GlassScriptPhysician profile
Tarik Lalwani
NPI 1376606087
$69,036.64
in general payments reported to CMS, 2019-2025
26 companies · $6,341 in 2025
The $6,341 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $7,499 · 2021: $1,795 · 2022: $7,743 · 2023: $5,105 · 2024: $19K · 2025: $6,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $7,175 · Food and Beverage: $5,938 · Travel and Lodging: $3,349 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $600 · Education: $30.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,600.00 |
| Consulting Fee | $7,175.00 |
| Food and Beverage | $5,938.12 |
| Travel and Lodging | $3,348.77 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $600.00 |
| Education | $30.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28,389.74 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $25,200.62 | 2021-2025 | Filspari, Thiola |
| Bayer Healthcare Pharmaceuticals INC. | $7,119.65 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $2,162.52 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $1,105.85 | 2024-2025 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $933.50 | 2019-2023 | Rayaldee |
| Amgen INC. | $803.90 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $565.18 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $413.10 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $369.99 | 2023-2024 | Jesduvroq, Benlysta |
| Vifor Pharma, INC. | $316.92 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $235.82 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $233.75 | 2019-2024 | Jynarque |
| Edwards Lifesciences Corporation | $132.26 | 2024 | Pascal |
| Daiichi Sankyo INC. | $131.08 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Silk Road Medical, INC. | $117.11 | 2019 | |
| Akebia Therapeutics INC | $112.29 | 2021-2022 | |
| Recor Medical INC | $104.66 | 2024 | Paradise Renal Denervation System |
| Mallinckrodt Enterprises LLC | $94.99 | 2019 | |
| Nuwellis, INC. | $91.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $89.47 | 2019 | |
| Fresenius USA Marketing, INC. | $85.14 | 2019-2023 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $81.15 | 2019-2025 | Voyxact |
| Ardelyx, INC. | $21.31 | 2025 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarik Lalwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.